Zai Lab Ltd. Unsponsored ADR Stock

$37.28

2.33% today

Nasdaq, Apr 03, 06:46 pm CET

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Zai Lab Ltd. Unsponsored ADR Stock price

$36.43

-15.06 29.25% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

-0.86 2.31%

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$3.98b
Enterprise Value	$3.25b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	8.14
P/S ratio (TTM) P/S ratio	9.96
P/B ratio (TTM) P/B ratio	4.67
Revenue growth (TTM) Revenue growth	49.59%
Revenue (TTM) Revenue	$398.99m
EBIT (operating result TTM) EBIT	$-282.12m
Free Cash Flow (TTM) Free Cash Flow	$-221.23m
Cash position	$879.67m
EPS (TTM) EPS	$-2.60
P/E forward	negative
P/S forward	7.05
EV/Sales forward	5.77
Short interest	8.33%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Zai Lab Ltd. Unsponsored ADR Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

15x Buy

88%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

Buy

88%

Hold

12%

Analyst Estimates with Stock Price Targets

Financial data from Zai Lab Ltd. Unsponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	399 399	50% 50% 100%
- Direct Costs	148 148	54% 54% 37%
Gross Profit	251 251	47% 47% 63%
- Selling and Administrative Expenses	278 278	6% 6% 70%
- Research and Development Expense	235 235	12% 12% 59%
EBITDA	-262 -262	27% 27% -66%
- Depreciation and Amortization	20 20	14% 14% 5%
EBIT (Operating Income) EBIT	-282 -282	25% 25% -71%
Net Profit	-257 -257	23% 23% -64%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Zai Lab Ltd. Unsponsored ADR Stock News

Neutral

Business Wire

●

8 days ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company's internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunothera...

Positive

Seeking Alpha

●

13 days ago

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by strong revenue growth and ambitious plans for future drug launches. The company aims to achieve $2bn in annual revenues by 2028, with key drugs like Vyvgart and Cobenfy leading the charge.

Positive

Seeking Alpha

●

14 days ago

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), a...

More Zai Lab Ltd. Unsponsored ADR News

Company Profile

Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.

Head office	Cayman Islands
CEO	Ying Du
Employees	1,869
Founded	2014
Website	www.zailaboratory.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now